Klinikum der Universität München

Advanced Breast Cancer: AGO Recommendations 2022 Focus on ABC6 Consensus Fortgeschrittenes Mammakarzinom ABC6-Konsens im Fokus der AGO-Empfehlungen 2022 (2022) Untch M, Fasching P, Haidinger R, Harbeck N, Jackisch C, Lüftner D, Müller V, et al. Journal article, Review article HRQoL with neoadjuvant pembrolizumab plus chemotherapy vs placebo plus chemotherapy, followed by adjuvant pembrolizumab vs placebo for early-stage TNBC: Results from KEYNOTE-522 (2022) Dent RA, Cortes J, Pusztai L, Mcarthur HL, Kuemmel S, Bergh J, Denkert C, et al. Conference contribution When to treat the pelvis in node-positive vulvar cancer: Results from the AGO-VOP.2 QS vulva study (2022) Hampl M, Jaeger A, Eulenburg C, Prieske K, Hambrecht J, Fuerst S, Klapdor R, et al. Conference contribution Model soups improve performance of dermoscopic skin cancer classifiers (2022) Maron RC, Hekler A, Haggenmüller S, von Kalle C, Utikal JS, Müller V, Gaiser M, et al. Journal article Occurrence and characteristics of patients with de novo advanced breast cancer according to patient and tumor characteristics – A retrospective analysis of a real world registry (2022) Muller V, Hein A, Hartkopf AD, Fasching P, Kolberg HC, Hadji P, Tesch H, et al. Journal article, Original article Medical Student Self-Assessment of Knowledge About Vaccinations and the Quality of Vaccination Training (2022) Roberts K, Streng A, Göttler D, Hartmann K, Peter-Kern M, Roggendorf H, Bogdan C, et al. Journal article Mid-term treatment-related cognitive sequelae in glioma patients (2022) Schlömer S, Felsberg J, Pertz M, Hentschel B, Löffler M, Schackert G, Krex D, et al. Journal article Does the Presence of Circulating Tumor Cells in High-Risk Early Breast Cancer Patients Predict the Site of First Metastasis-Results from the Adjuvant SUCCESS A Trial (2022) Trapp EK, Fasching P, Fehm T, Schneeweiss A, Mueller V, Harbeck N, Lorenz R, et al. Journal article Molecular Subtyping of Invasive Breast Cancer Using a PAM50-Based Multigene Expression Test-Comparison with Molecular-Like Subtyping by Tumor Grade/Immunohistochemistry and Influence on Oncologist's Decision on Systemic Therapy in a Real-World Setting (2022) Erber R, Angeloni M, Stöhr R, Lux MP, Ulbrich-Gebauer D, Pelz E, Bankfalvi A, et al. Journal article Immuntherapie bei neuroendokrinen Tumoren: Zeitpunkt und Zielgruppe (2022) Auernhammer CJ, Pavel ME Journal article